The study evaluated the quality of reporting and bias in Chinese COVID-19 clinical trials. They looked at 172 trials registered before April 2, 2020. Most trials included basic information like objectives and outcomes, but many lacked details on blinding and randomization. The quality of reporting was lower than expected, especially in randomization and blinding. Most trials had low risk of bias in random sequence generation, but few had low risk in allocation concealment. Researchers should follow the CONSORT statement when designing trials.